{
    "nct_id": "NCT05651932",
    "official_title": "A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor That Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma",
    "inclusion_criteria": "Key Inclusion Criteria for Dose-Expansion:\n\n* ≥ 18 years of age\n* ECOG score ≤ 1\n* Multiple myeloma (as per IMWG)\n\n  * ≥ 3 prior lines of therapy, including a PI, an IMiD, and an anti-CD38 antibody\n  * Patients must be refractory to their last prior therapy\n  * Cohorts A1/A2: Patients must have exhausted available therapeutic options that are expected to provide a meaningful clinical benefit, either through disease relapse, treatment refractory disease, intolerance, or refusal of the therapy\n  * t(4;14) confirmed by standard of care FISH testing\n* Measurable disease, including at least 1 of the following criteria:\n\n  * Serum M protein ≥ 0.50 g/dL (by SPEP)\n  * Serum IgA ≥ 0.50 g/dL (IgA myeloma patients)\n  * Urine M protein ≥ 200 mg/24 h (by UPEP)\n  * sFLC involved light chain ≥ 10 mg/dL (100 mg/L) (patients with abnormal sFLC ratio)\n  * Bone marrow plasma cells ≥ 30% (if only criterion for measurability)\n* Agreement to enroll into the REMS program (Cohort D- pomalidomide cohort only)\n\nKey Exclusion Criteria for Dose-Expansion:\n\n* Treatment with the following therapies in the specified time period prior to first dose:\n\n  * Carfilzomib in the immediate last prior line of therapy for patients enrolled in Cohorts C1 and C2\n  * Pomalidomide in the immediate last prior line of therapy for patients enrolled in cohort D\n  * Radiation, chemotherapy, immunotherapy, or any other anticancer therapy ≤ 2 weeks\n  * Cellular therapies ≤ 8 weeks\n  * Autologous transplant < 100 days\n  * Allogenic transplant ≤ 6 months, or > 6 months with active GVHD\n  * Major surgery ≤ 4 weeks\n* Current plasma cell leukemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, solitary bone lesion or bone lesions as the only evidence for plasma cell dyscrasia, myelodysplastic syndrome or a myeloproliferative neoplasm or light chain amyloidosis\n* MM with extramedullary disease\n* Active CNS disease\n* Inadequate bone marrow function\n* Inadequate renal, hepatic, pulmonary, and cardiac function\n* Active, ongoing, or uncontrolled systemic viral, bacterial, or fungal infection. Permitted prophylactic medications, antimicrobials or antiretroviral therapies defined in protocol.\n* Use of acid reducing agents and strong inhibitors or inducers of CYP3A4 within 14 days or 5 half-lives prior to first dose\n* Strong CYP1A2 inhibitors for patients receiving pomalidomide (Cohort D)\n* Active malignancy not related to myeloma requiring therapy within < 2 years prior to enrollment, or not in complete remission, with exceptions defined in protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}